Published in
American Society for Microbiology, Antimicrobial Agents and Chemotherapy, 1(66), 2022
DOI: 10.1128/aac.01535-21
Links
Tools
Identification of a Proteasome-Targeting Arylsulfonamide with Potential for the Treatment of Chagas’ Disease
Journal article published in 2022 by
Marta L. Lima,
Lindsay B. Tulloch,
Victoriano Corpas-Lopez,
Sandra Carvalho,
Richard J. Wall 
,
Rachel Milne,
Eva Rico,
Stephen Patterson,
Ian H. Gilbert,
Sonia Moniz,
Lorna MacLean,
Leah S. Torrie,
Carmine Morgillo,
David Horn ,
Fabio Zuccotto
and other authors.
,
Rachel Milne,
Eva Rico,
Stephen Patterson,
Ian H. Gilbert,
Sonia Moniz,
Lorna MacLean,
Leah S. Torrie,
Carmine Morgillo,
David Horn ,
Fabio Zuccotto
and other authors.
This paper is made freely available by the publisher.
Full text: Download
Data provided by 
Abstract
Phenotypic screening identified an arylsulfonamide compound with activity against Trypanosoma cruzi , the causative agent of Chagas’ disease. Comprehensive mode of action studies revealed that this compound primarily targets the T. cruzi proteasome, binding at the interface between β4 and β5 subunits that catalyze chymotrypsin-like activity.